Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Arthrosurface, Inc.
Vancouver biotech is building a pipeline of candidates for rare, severe chronic kidney disease. It has an oral drug in Phase III and an antibody candidate in mid-stage development for IGA nephropathy.
BeiGene’s $3.5bn Shanghai IPO and CANbridge’s Hong Kong listing, as well as Dizal’s offering on the STAR market and five financing rounds totaling $508.5m help set a record for Chinese biotech fundraising in the last month of 2021.
Astellas inks agreement with Dyno Therapeutics for access to its CapsidMap platform for novel AAV vectors. Taiho takes option to Arcus TIGIT-targeted antibody candidates.
Orthopedic implant company Arthrosurface is hoping to get hand surgeons' attention with its new allograft thumb implant to treat osteoarthritis.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Anika Therapeutics, Inc
- Arthrosurface®, Inc
- Arthrosurface® Incorporated
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.